Taiwan
· Delayed Price · Currency is TWD Intech Biopharm Statistics
Total Valuation
Intech Biopharm has a market cap or net worth of TWD 2.50 billion. The enterprise value is 3.56 billion.
| Market Cap | 2.50B |
| Enterprise Value | 3.56B |
Important Dates
The last earnings date was Tuesday, May 6, 2025.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Intech Biopharm has 137.94 million shares outstanding. The number of shares has increased by 13.97% in one year.
| Current Share Class | 137.94M |
| Shares Outstanding | 137.94M |
| Shares Change (YoY) | +13.97% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 2.26% |
| Float | 74.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 76.43 |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.32 |
| EV / Sales | 108.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.56 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 1.74.
| Current Ratio | 0.89 |
| Quick Ratio | 0.49 |
| Debt / Equity | 1.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.41 |
| Interest Coverage | -10.73 |
Financial Efficiency
Return on equity (ROE) is -41.87% and return on invested capital (ROIC) is -9.98%.
| Return on Equity (ROE) | -41.87% |
| Return on Assets (ROA) | -9.03% |
| Return on Invested Capital (ROIC) | -9.98% |
| Return on Capital Employed (ROCE) | -19.09% |
| Revenue Per Employee | 362,978 |
| Profits Per Employee | -4.24M |
| Employee Count | 90 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 2.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.41% in the last 52 weeks. The beta is -0.01, so Intech Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -32.41% |
| 50-Day Moving Average | 20.47 |
| 200-Day Moving Average | 25.97 |
| Relative Strength Index (RSI) | 43.67 |
| Average Volume (20 Days) | 34,149 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Intech Biopharm had revenue of TWD 32.67 million and -381.66 million in losses. Loss per share was -2.77.
| Revenue | 32.67M |
| Gross Profit | -165.03M |
| Operating Income | -367.78M |
| Pretax Income | -381.66M |
| Net Income | -381.66M |
| EBITDA | -280.19M |
| EBIT | -367.78M |
| Loss Per Share | -2.77 |
Balance Sheet
The company has 207.19 million in cash and 1.27 billion in debt, giving a net cash position of -1.06 billion or -7.69 per share.
| Cash & Cash Equivalents | 207.19M |
| Total Debt | 1.27B |
| Net Cash | -1.06B |
| Net Cash Per Share | -7.69 |
| Equity (Book Value) | 728.13M |
| Book Value Per Share | 5.27 |
| Working Capital | -48.37M |
Cash Flow
In the last 12 months, operating cash flow was -320.64 million and capital expenditures -51.51 million, giving a free cash flow of -372.16 million.
| Operating Cash Flow | -320.64M |
| Capital Expenditures | -51.51M |
| Free Cash Flow | -372.16M |
| FCF Per Share | -2.70 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,125.81% |
| Pretax Margin | -1,168.29% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Intech Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.97% |
| Shareholder Yield | -13.97% |
| Earnings Yield | -15.29% |
| FCF Yield | -14.91% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |